Dacomitinib Tablet shortage
Dacomitinib Tablet is currently listed in shortage by the FDA. The FDA lists 3 affected products. This page was last refreshed from FDA data on Sep 24, 2026.
Pfizer is permanently stopping production of Vizimpro (dacomitinib) tablets. No other manufacturer makes this medicine, so none of the 15 mg, 30 mg, or 45 mg strengths currently have a listed available source.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Dacomitinib Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jun 8, 2026Currently in shortage3 of 3 products affected.
-
Jun 8, 2026First reported to the FDA3 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Pfizer Inc. 📞 800-533-4535 3 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Vizimpro, Tablet, 15 mg (NDC 0069-0197-30) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Vizimpro, Tablet, 45 mg (NDC 0069-2299-30) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Vizimpro, Tablet, 30 mg (NDC 0069-1198-30) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Dacomitinib Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Dacomitinib Tablet? options further down this page.
Why is Dacomitinib Tablet in shortage?
Pfizer has reported to the FDA that it is permanently stopping the manufacturing of Vizimpro (dacomitinib) tablets in all three strengths — the 15 mg, 30 mg, and 45 mg tablets. This means all three versions of this specific product from Pfizer are being discontinued, not just one particular size or dose.
No specific reason was shared publicly by Pfizer for why they are stopping production. Because this reflects only what Pfizer has reported to the FDA, it applies specifically to their Vizimpro brand — this report does not speak to any other manufacturers of this medicine.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Dacomitinib Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Dacomitinib Tablet?
Dacomitinib (also sold as Vizimpro) is currently on the FDA drug-shortage list. I want you to know that this note is meant to guide your next steps calmly, not to alarm you.
All three strengths are affected. The 15 mg, 30 mg, and 45 mg tablets each have no available source reported right now. The reason given is that the manufacturer of record, Pfizer, is discontinuing production of this medicine. Because this is listed as a discontinuation rather than a temporary supply gap, this problem may be permanent — which makes a conversation with your prescriber the most important step.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own. Keep taking it as prescribed while you sort out next steps.
- Ask your pharmacy to check with wholesalers and other manufacturers — local stock can differ from national reports, and they may still locate remaining supply.
- Because this medicine is being discontinued, contact your prescriber soon to discuss your options, such as a clinician-chosen alternative that fits your treatment plan.
- The manufacturer's contact number is listed on this page for reference, though pharmacies usually handle those calls.
This is general information from national, manufacturer-reported data and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 3 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Vizimpro 15 mg | Pfizer | 30 tablets | — | — | FDA listed |
| Vizimpro 45 mg | Pfizer | 30 tablets | — | — | FDA listed |
| Vizimpro 30 mg | Pfizer | 30 tablets | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Dacomitinib Tablet — that fall in the same broad treatment class (antineoplastic systemic enzyme inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Dacomitinib Tablet shortage FAQs
Is Dacomitinib Tablet in shortage?
Which products are affected?
When will Dacomitinib Tablet be available again?
What should I do if I take Dacomitinib Tablet?
Still have a question about the Dacomitinib Tablet shortage?
Ask a pharmacist about this shortage →View Dacomitinib Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.